BINEX Co. Ltd (053030) - Total Liabilities
Based on the latest financial reports, BINEX Co. Ltd (053030) has total liabilities worth ₩117.14 Billion KRW (≈ $79.38 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BINEX Co. Ltd - Total Liabilities Trend (2004–2024)
This chart illustrates how BINEX Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is BINEX Co. Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
BINEX Co. Ltd Competitors by Total Liabilities
The table below lists competitors of BINEX Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sparebank 1 Nordvest
OL:SNOR
|
Norway | Nkr25.68 Billion |
|
Shanghai Highly Group Co Ltd B
SHG:900910
|
China | $15.67 Billion |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
Korea | ₩191.48 Billion |
|
Net Lease Office Properties
NYSE:NLOP
|
USA | $84.00 Million |
|
E-Data Teknoloji Pazarlama AS
IS:EDATA
|
Turkey | TL374.63 Million |
|
Toya SA
WAR:TOA
|
Poland | zł173.66 Million |
|
Kangda International Environmental Company Limited
STU:27K
|
Germany | €12.37 Billion |
|
Atlantic Lithium Ltd
AU:A11
|
Australia | AU$3.35 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down BINEX Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BINEX Co. Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BINEX Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BINEX Co. Ltd (2004–2024)
The table below shows the annual total liabilities of BINEX Co. Ltd from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩97.78 Billion ≈ $66.26 Million |
+29.19% |
| 2023-12-31 | ₩75.69 Billion ≈ $51.29 Million |
-29.14% |
| 2022-12-31 | ₩106.80 Billion ≈ $72.38 Million |
+16.00% |
| 2021-12-31 | ₩92.07 Billion ≈ $62.39 Million |
-4.96% |
| 2020-12-31 | ₩96.88 Billion ≈ $65.65 Million |
+129.10% |
| 2019-12-31 | ₩42.29 Billion ≈ $28.66 Million |
+3.17% |
| 2018-12-31 | ₩40.99 Billion ≈ $27.78 Million |
+5.04% |
| 2017-12-31 | ₩39.02 Billion ≈ $26.44 Million |
+6.76% |
| 2016-12-31 | ₩36.55 Billion ≈ $24.77 Million |
+14.32% |
| 2015-12-31 | ₩31.97 Billion ≈ $21.67 Million |
+28.80% |
| 2013-12-31 | ₩24.82 Billion ≈ $16.82 Million |
-52.18% |
| 2012-12-31 | ₩51.90 Billion ≈ $35.17 Million |
+72.44% |
| 2011-12-31 | ₩30.10 Billion ≈ $20.40 Million |
+105.73% |
| 2007-12-31 | ₩14.63 Billion ≈ $9.91 Million |
+1.63% |
| 2006-12-31 | ₩14.40 Billion ≈ $9.76 Million |
+6.15% |
| 2005-12-31 | ₩13.56 Billion ≈ $9.19 Million |
-26.46% |
| 2004-12-31 | ₩18.44 Billion ≈ $12.50 Million |
-- |
About BINEX Co. Ltd
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more